Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Dokuz Eylul University, Izmir, Türkiye.
Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Dokuz Eylul University, Izmir, Türkiye.
Immunol Lett. 2023 Oct;262:1-6. doi: 10.1016/j.imlet.2023.08.002. Epub 2023 Aug 18.
To evaluate anti-RBD IgG antibody levels and neutralizing antibody titers between the health care workers (HCWs) with breakthrough SARS-CoV-2 infection and controls.
In this nested case-case control study, we followed 548 vaccinated HCWs with homologous (only with inactivated vaccine) or heterologous (both with inactivated and BNT162b2 vaccine) vaccination for 11 months, prospectively. We obtained blood samples from the participants for quantitative anti-RBD IgG and surrogate neutralization test. The participants with SARS-CoV-2 PCR positivity (at least 14 days after the last vaccination) were considered breakthrough infection. We chose 1:2 matched controls from the cohort, according to age, sex and vaccination status. We used R version 4.0.2 for the statistical analysis.
Sixty-five cases and 130 controls were included in the study. The number of the breakthrough infections in HCWs were correlated with the pandemic waves in Türkiye and peaked during Omicron outbreak. The median age of the cases was 39 and 78.5% were female. The cases had more comorbidities than controls, significantly (p = 0.021). All cases experienced no or mild symptoms and recovered completely. Both pre-infection anti-RBD antibody and neutralizing antibody titers did not differ between cases and matched controls (p = 0.767, p = 0.628).
In this study, we showed that there was no comparable difference in humoral response after homologous or heterologous vaccination between the cases of breakthrough infection and matched controls. Compliance with infection control measures should be ensured, in combination with vaccination.
评估突破性 SARS-CoV-2 感染的医护人员（HCWs）与对照者之间的抗 RBD IgG 抗体水平和中和抗体滴度。
在这项嵌套病例对照研究中，我们前瞻性地随访了 548 名接种同源（仅接种灭活疫苗）或异源（接种灭活疫苗和 BNT162b2 疫苗）疫苗的接种 HCWs 11 个月。我们从参与者中获得定量抗 RBD IgG 和替代中和试验的血样。将 SARS-CoV-2 PCR 阳性（最后一次接种后至少 14 天）的参与者视为突破性感染。我们根据年龄、性别和接种状态从队列中选择了 1:2 的匹配对照者。我们使用 R 版本 4.0.2 进行统计分析。
该研究纳入了 65 例病例和 130 例对照者。HCWs 中的突破性感染数量与土耳其的大流行波相关，在奥密克戎爆发期间达到峰值。病例的中位年龄为 39 岁，78.5%为女性。病例的合并症比对照者多，差异有统计学意义（p=0.021）。所有病例均经历无症状或轻症，完全康复。感染前的抗 RBD 抗体和中和抗体滴度在病例和匹配对照者之间无差异（p=0.767，p=0.628）。
在这项研究中，我们表明，在同源或异源疫苗接种后的突破性感染病例与匹配对照者之间，体液反应没有可比差异。应结合疫苗接种，确保遵守感染控制措施。
